To examine whether tumor growth may be altered by these opposing immune-modulating effects in vivo, we evaluated the impact of PTIS blockade indirectly by disrupting IFN-regulation or directly by blocking one secretory factor, such as IL6. Here, IFNA1 is linked to neoplasm.